Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
295 GBX | 0.00% | -6.35% | -16.31% |
Business Summary
Number of employees: 143
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapy
55.3
%
| 31 | 69.0 % | 23 | 55.3 % | -25.26% |
Program-related
27.8
%
| 5 | 10.4 % | 11 | 27.8 % | +148.38% |
Drug Discovery
16.9
%
| 9 | 20.6 % | 7 | 16.9 % | -23.14% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 44 | 100.0 % | 41 | 100.0 % | -6.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 27/23/27 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 01/05/01 |
Corporate Officer/Principal | - | 21/23/21 | |
Gene Zhu
LAW | General Counsel | - | - |
Jill Mayer
HRO | Human Resources Officer | - | 01/18/01 |
Thomas Ross
SAM | Sales & Marketing | 63 | 15/14/15 |
Steven Nardi
PRN | Corporate Officer/Principal | - | 13/20/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 01/22/01 |
Art Mandell
BRD | Director/Board Member | 71 | 01/06/01 |
Will Brooke
BRD | Director/Board Member | 68 | 01/04/01 |
Stanley Erck
BRD | Director/Board Member | 76 | 01/05/01 |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 01/05/01 |
John Johnston
BRD | Director/Board Member | 65 | 01/16/01 |
Richard Douglas
CHM | Chairman | 71 | 12/18/12 |
Yasir Al-Wakeel
BRD | Director/Board Member | 42 | 15/21/15 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 15/21/15 |
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 104,128,650 | 97,898,738 ( 94.02 %) | 0 | 94.02 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.31% | 384M | |
+8.69% | 219B | |
+6.69% | 183B | |
+10.90% | 133B | |
+25.41% | 108B | |
+0.27% | 63.06B | |
+12.72% | 52.02B | |
+3.96% | 48.2B | |
+0.40% | 40.37B | |
+15.03% | 39.35B |
- Stock Market
- Equities
- MXCT Stock
- Company MaxCyte, Inc.